

# DRUG DISCOVERY INITIATIVE TOOLBOX

## TOOL LISTING SUBMISSION FORM

Dear Colleague:

The Children's Tumor Foundation Drug Discovery Initiative (DDI) funds and facilitates early stage screening of candidate therapies for neurofibromatosis (NF). The DDI Toolbox drives resource sharing within the NF research community, and encourages biotech and pharmaceutical companies to make available any drugs that may have potential as candidate NF therapies, and to collaborate and partner with the NF community to test drugs in NF preclinical models.

We invite submission of research 'tools' such as candidate NF therapeutics, cell lines, mouse models, methods and protocols. These will be publicly listed at: <http://ctf.org/For-Scientists/ddi-toolbox.html>. Tools may be submitted on a rolling basis by completing the attached form and submitting to me by email at [khs@ctf.org](mailto:khs@ctf.org).

Listing your tool in the DDI Toolbox is simply 'willingness to share'. Sharing of tools will be governed by exchange of Material Transfer Agreements, etc. between sharing institutions/entities. You may remove your tool listing from the DDI Toolbox at any time by contacting me.

Anyone interested in collaborating with you will first contact the Foundation. You will be notified, and if you wish to pursue the opportunity, the Foundation can make the introduction.

Partnerships formed via the DDI Toolbox may then apply for a CTF DDI Award (<http://ctf.org/For-Scientists/ddi-awards.html>) but are encouraged to seek support elsewhere.

Thanks for your participation in DDI!



Kim Hunter-Schaedle, Ph.D.  
Chief Scientific Officer, Children's Tumor Foundation  
[khs@ctf.org](mailto:khs@ctf.org)  
212-344-6633 x231

## DRUG DISCOVERY INITIATIVE TOOLBOX SUBMISSION FORM

### Contact Person:

Name (Last, First)	Antonawich, Francis, Ph.D.
Institution or Company Name:	Garnett McKeen Laboratory, Inc.
E-mail:	frank@garnettmckeenlabs.net
Telephone & Fax#:	Tel. (631) 218-3400 Fax. (631) 218-6478

### Tool Type

Tool Type
<input type="checkbox"/> In vitro model - cell line, etc.
<input type="checkbox"/> In vivo model - transgenic mouse, etc.
<input checked="" type="checkbox"/> Drug
<input type="checkbox"/> Method or protocol
<input type="checkbox"/> Other (describe) ____

**PLEASE PROVIDE A BRIEF DESCRIPTION OF THE TOOL. INCLUDE LITERATURE REFERENCES WHERE AVAILABLE (use as much space as you wish).**

Garnett McKeen Laboratory, Inc. produces a palladium  $\alpha$ -lipoic acid complex (PdLA) formulation that demonstrates non-toxic chemotherapeutic properties. It has completed a Phase I dose-escalation safety study and is currently being utilized at Stony Brook University as adjunctive support in a glioblastoma multiforme (GBM) study. We would like to first explore its use in pre-clinical in-vitro studies using your NF cell lines and would be willing to collaborate with in-vivo studies and translational Neurofibromatosis application.